Our mission is to raise awareness and
transform the treatment of severe
aortic regurgitation

John joined JenaValve in 2019 bringing 30 years of experience and is a proven leader in the medical device industry in both start-up organizations and publicly traded companies leading IPO and acquisition strategies.

Throughout his career, John has held several medical device leadership roles. He was the CEO of Endonetics, from 1997 until its acquisition by Medtronic in 2002. From 2002 to 2004, John served as the CEO of Solace Therapeutics. From 2004 until 2010, he was President and CEO at Micrus Endovascular Corporation, leading its IPO efforts in 2005, capturing significant market share and acquisition by Johnson & Johnson in 2010. Before joining JenaValve, John served as the President and CEO of ReVision Optics.

John also serves on the Board of Directors at Cerus Endovascular and CerebroTech Medical Systems, both privately held start-up device medical device companies focused on the treatment of hemorrhagic and diagnosis of ischemic stroke, respectively.

He is a named inventor on more than 20 patents. He has broad and applicable experience leading high-tech medical device emerging growth organizations through market approvals, market access, high growth, and successful strategic transactions, including IPOs and M&A activities.

John received his degree from Cornell University.

Peter joined the JenaValve team as Chief Commercial Office in October 2020 and brings over 35 years of sales and commercial leadership experience in the cardiovascular space.

Prior to this, he served as President and Chief Commercial Officer of SynCardiaSystems, LLC, a medical device company that manufactures the total artificial heart.

In addition, Pete has held multiple roles at Medtronic, a medical technology and services company, including as Senior Director Cardiac Surgery Sales and Structural Heart National Accounts and as Director of U.S. TAVR Sales and Structural Heart Strategy.

Prior to that, he spent over 28 years with St. Jude Medical, serving in multiple roles, including VP of Commercial Strategy and Customer Engagement, Vice President Global Marketing – Structural Heart, Division Vice President – Cardiac Rhythm Management and Electrophysiology, and Division Vice President of Cardiovascular, Structural Heart, Cardiac Surgery.

Peter earned his Bachelor’s Degree in Communications from Fordham University, in New York City.

A leader in interventional cardiology, Dr. Pinto joins JenaValve following more than 20 years of performing complex coronary, structural, and peripheral vascular procedures with and without circulatory assistance. Before joining JenaValve, Dr. Pinto was an associate professor of Medicine at Harvard Medical School and served as the Chief of the Interventional Cardiology section at Beth Israel Deaconess Medical Center. He is also a trained proctor for the newest transcatheter valves and invited around the world to advise and perform interventional cardiology procedures.

Through the publication of over 100 original manuscripts, case reports, reviews, editorials, and book chapters, Dr. Pinto has pursued research interests in a wide variety of topics and studies, including outcomes and economic analyses for acute myocardial infarction and unstable angina. He has authored numerous device trials for both coronary and peripheral circulations. In addition, Dr. Pinto serves as a manuscript reviewer for NEJM, JACC, Circulation (AHA), and others and is also on the editorial board of Circulation, CCI, and JACC.

Dr. Pinto earned his AB in Biological Sciences from Dartmouth College, his MD in Medicine from Georgetown University, and his MPH in Clinical Effectiveness and Biostatistics from the Harvard T.H. Chan School of Public Health.

Matt brings more than 15 years of investor relations, strategic finance, and business operations experience in the medical technology industry. Most recently, Matt served as VP of Investor Relations & Business Operations at Procept BioRobotics where he led investor communications, enterprise-wide financial strategy, and commercial planning as the company scaled from less than $30 million to approximately $400 million in revenue. He oversaw budgeting, forecasting, capital allocation, and long-range planning while building trusted relationships across the med-tech investor community.

Prior to Procept BioRobotics, Matt served as Managing Director at Gilmartin Group, a healthcare-focused strategic advisory firm, where he advised medical device executives on capital markets strategy and investor communications, including serving as a strategic advisor to JenaValve. He also previously worked in equity research at Piper Sandler and William Blair. He holds a Finance degree from The Ohio State University and completed the CFA Program in 2014.

Ed joined JenaValve as Chief Technology Officer in 2026. Throughout his 25 years in cardiovascular medical devices, Ed led R&D organizations that developed innovative new cardiac therapies and drove their commercial launch and global expansion. Ed brings deep expertise in structural heart and transcatheter valve replacement technologies to his role on the JenaValve leadership team.

Before joining JenaValve, Ed served as Vice President of R&D for TAVR & Congenital and subsequently Vice President of R&D for Mitral & Tricuspid at Medtronic Structural Heart. Over the course of eleven impactful years, Ed led a global organization accountable for developing transcatheter valve replacement therapies spanning R&D execution, clinical investigation, commercialization, and portfolio strategy. Previously, Ed spent over a decade at St. Jude Medical (acquired by Abbott) in senior R&D and business development roles. There, his teams built a portfolio of novel cardiac and heart failure therapies through a blend of internal development and inorganic investment. Ed also has experience in management and strategy consulting for large global organizations.

Ed earned a Bachelor of Science in Mechanical Engineering from MIT, a Master of Science in Engineering from the University of Texas at Austin, and an MBA from MIT Sloan School of Management.

Tonya joined the JenaValve team as Vice President of Regulatory Affairs in May of 2026 and brings over 20 years of Regulatory Affairs, Clinical Affairs, and Quality Assurance leadership experience in the medical device industry.

Most recently, Tonya served as Principal Consultant at Regulatory Scientist, Inc., where she supported multiple medical device companies through their premarket and post market journeys. Prior to her consulting work, Tonya spent more than a decade at ReVision Optics, ultimately serving as Vice President of Global Regulatory Affairs and Quality Assurance. Earlier in her career, Tonya served as an Engineer Technician at the U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH).

Greg joined JenaValve in 2016, bringing over 25 years of proven leadership experience in the design and development of medical device technologies in neurovascular, peripheral vascular and cardiovascular markets. Greg has been an instrumental leader in the development of JenaValve’s transcatheter heart valve system and future technology pipeline.

Greg has a dedicated career in developing innovative medical technology and brings a breadth of product development experience to the organization. Before joining JenaValve, Greg established a successful R&D consulting firm assisting clients ranging from medical device start-ups to Fortune 500 corporations in the development and commercialization of various novel interventional devices. He was previously Chief Technology Officer for INCUMEDx, an R&D-focused medical device incubator of various neurovascular/cardiovascular devices and surgical implants. Greg also held several leadership roles over 16 years at Boston Scientific Neurovascular and Boston Scientific Japan in R&D and Advanced Technology groups in developing multiple, commercial catheter, guidewire, and embolic coil products.

Greg is an innovator and has over 30 issued patents in various medical device fields. He received his education from San Jose State University and earned a Bachelor’s Degree in Mechanical Engineering with a minor in Business.

Connie joined JenaValve in 2020 and brings more than a decade of diverse Human Resources experience to the team. Connie is an established business professional with deep expertise in global human resources and has served both the optical and MedTech industries.

Connie is a passionate advocate for employee engagement, organizational development, and inclusive workplace culture. She brings a strong commitment to DEI initiatives and culture transformation, ensuring that HR strategies align with business goals and employee well-being. Her prior roles at HydraFacial as an HR Business Partner and at Carl Zeiss Vision managing HR and corporate facilities have shaped her collaborative and future-forward leadership style.

Connie holds an MBA with a specialization in Human Resources Management from California State University, Long Beach. She earned her BA in Women’s Studies from Arizona State University, where she developed a foundation in advocacy and equity that continues to influence her leadership approach. She is dedicated to fostering agile, high-performing teams and creating people-first cultures that drive innovation and long-term success.

Dave joined JenaValve in March 2026 as Vice President of Clinical Affairs, contributing over 25 years of executive leadership in medical devices, with particular depth in interventional and catheter-based therapies, regulatory strategy, and global trial execution.

Before joining JenaValve, Dave held clinical and product development leadership roles at Stryker Neurovascular, including serving as leader of clinical and medical affairs. During his tenure he built and scaled a global clinical organization, secured FDA IDE and PMA approvals through large-scale clinical trials, expanded indications through real-world evidence, and drove industry collaboration through active participation at MDIC.

Dave also served as Vice President of Global Clinical Affairs at Danaher’s Beckman Coulter Diagnostics, leading an enterprise integration of multiple operating companies into a unified Clinical Center of Excellence — overseeing a broad portfolio of concurrent global studies and delivering more than 50 regulatory approvals across FDA, EU, and NMPA with a spotless inspection record.

Dave earned his Master of Science in Materials Science Engineering and his Bachelor of Science from Rutgers University, his MBA from Santa Clara University’s Leavey School of Business, and holds a PMP certification.

Maria Jose brings more than 25 years of executive leadership experience in quality and regulatory affairs across medical devices, diagnostics, and combination product environments. She has a proven track record of building and scaling compliant Quality Management Systems (QMS), advancing regulatory workflows, and leading global inspection readiness programs across organizations.

Most recently, Maria Jose served as Senior Director of Quality & Compliance at Johnson & Johnson Electrophysiology. Prior to J&J, she served as Head of Quality & Compliance at Accriva Diagnostics, leading global QMS and validation teams across multiple markets. She also held quality and regulatory roles at Volcano Corporation, CryoCor, and Medtronic Vascular. Maria Jose holds advanced degrees from Instituto Tecnologico de Monterrey and is certified as a Six Sigma Black Belt and ISO 13485 Lead Auditor.